发明名称 |
PHARMACOLOGICALLY ACCEPTABLE SALT OF [1,3,4]OXADIAZOLE COMPOUND OR HYDRATE THEREOF |
摘要 |
<p>A pharmacologically acceptable salt of a compound (1), which has an FXa inhibitory effect and is useful as a pharmaceutical compound for prevention/treatment of thrombotic and/or embolic diseases, a hydrate thereof, a crystal of the salt or hydrate, and methods for commercially producing the same. Specifically disclosed is a pharmacologically acceptable salt of N1-(5-chloropyridin-2-yl)-N2-[(1S,2R,4S)-2-{[(5-methyl- 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}-4-([1,3,4]oxadiazol-2-yl)cyclohexyl]ethanediamide, a hydrate thereof, or a crystal of the salt or hydrate.</p> |
申请公布号 |
WO2010058751(A1) |
申请公布日期 |
2010.05.27 |
申请号 |
WO2009JP69431 |
申请日期 |
2009.11.16 |
申请人 |
DAIICHI SANKYO COMPANY,LIMITED;ONO, MAKOTO;YOSHIDA, SHOKO;NAGASAWA, HIROSHI |
发明人 |
ONO, MAKOTO;YOSHIDA, SHOKO;NAGASAWA, HIROSHI |
分类号 |
C07D513/04;A61K31/444;A61P7/02;A61P9/10;A61P11/00;A61P43/00 |
主分类号 |
C07D513/04 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|